Merck KGaA (MKGAF)
(Delayed Data from OTC)
$175.03 USD
-6.97 (-3.83%)
Updated Aug 2, 2024 11:43 AM ET
4-Sell of 5 4
A Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
MKGAF 175.03 -6.97(-3.83%)
Will MKGAF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MKGAF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MKGAF
Here's What Could Help Merck KGaA (MKGAF) Maintain Its Recent Price Strength
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
MKGAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Merck KGaA (MKGAF) a Good Fit for 'Trend Investing'
HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
Other News for MKGAF
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth Amid Mixed ...
Merck KGaA reports Q2 results
Merck KGaA falls after discontinuing head and neck cancer therapy
J.P. Morgan’s top picks within Defensives